Fresenius Medical Care AG

FME

DE0005785802

Healthcare Facilities & Services

Real-time Estimate Tradegate Other stock markets 08:20:19 2026-06-10 am EDT			5-day change	1st Jan Change
39.02 ^EUR	+1.00%		+8.61%	-4.02%

Jun. 09	FMC FRESENIUS MEDICAL CARE AG : UBS keeps a Sell rating	ZD
Jun. 08	Clínica Baviera, the copy-paste machine

FMC FRESENIUS MEDICAL CARE AG : UBS reaffirms its Sell rating

Published on 05/06/2026 at 07:09 am EDT

MarketScreener with dpa-AFX Analyser

FRESENIUS MEDICAL CARE AG

+1.06%

The analyst from UBS, Graham Doyle, maintains his advice to sell. The target price is unchanged at EUR 37.

Latest news about Fresenius Medical Care AG

Jun. 09	FMC FRESENIUS MEDICAL CARE AG : UBS keeps a Sell rating	ZD
Jun. 08	Clínica Baviera, the copy-paste machine
Jun. 05	Deutsche Börse News: Bonds: 'Sideways Market Ahead of ECB Meeting'	DP
Jun. 03	Fresenius Medical Care Launches Kinexus Worldwide, A Unified Digital Platform to Support Home Dialysis	CI
Jun. 02	Fresenius opens medical nutrition center	DP
Jun. 01	FMC FRESENIUS MEDICAL CARE AG : UBS gives a Sell rating	ZD
May. 28	Fresenius Medical Care Launches First Tranche of Share Repurchase Program	MT
May. 28	Fresenius Medical Care to commence share buyback program on May 28	RE
May. 28	Fresenius Medical Care AG commences an Equity Buyback Plan for 279,288,885 shares, representing 10% of its issued share capital, under the authorization approved on May 21, 2026.	CI
May. 27	Fresenius Medical Care Highlights New Renal Research and Innovation At Era Congress 2026	CI
May. 26	European Stocks Close Mixed Tuesday Amid Renewed Strains in US-Iran Talks	MT
May. 26	German Shares Retreat Amid Revived US-Iran Escalation Fears	MT
May. 26	Fresenius Medical Care to Launch New EUR1 Billion Share Buyback	MT
May. 26	Fresenius Medical Care Plans $1.16 Billion Share Buyback Program	MT
May. 26	FMC approves another share buyback program of approximately one billion euros	DP

Chart Fresenius Medical Care AG

Duration

Period

FME: Dynamic Chart

Fresenius Medical Care AG is the world's leading supplier of services and equipment for patients with kidney problems. Net sales break down by activity as follows: - clinical care services (75.2%): operated, at the end of 2025, 3,601 institutions; - manufacturing of dialyzers and related products (24.8%): hemo-dialysis and pediatric dialysis machines, etc. The group also offers therapies accompanied by care and treatment for dialysis patients.

Employees

108,165

Sector

Healthcare Facilities & Services

Calendar

Earnings release - Q2 2026

More about the company